Although Orencia SC Enjoys a High Trial and Usage Rate One Year Post-Launch in Rheumatoid Arthritis, It Remains a Second-Line Therapy after TNF Inhibitors According to a Recent BioTrends Report Business Wire EXTON, Pa. -- December 17, 2012 BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that after one full year on the market, over 75 percent of surveyed rheumatologists have a high familiarity with Bristol-Myers Squibb’s Orencia SC. Additionally, the vast majority of surveyed physicians have prescribed Orencia SC, and both the familiarity and usage represent significant increases versus the previous three waves of this LaunchTrends: Orencia SC report. According to surveyed physicians, the majority of Orencia SC patient starts were switched from other agents, primarily the more established TNF inhibitors – Abbott’s Humira, Pfizer/Amgen’s Enbrel and Janssen Biotech’s Remicade. This trend has steadily increased over the four waves, while the percent switching from Orencia IV has steadily decreased over the same time period. In the next six months, surveyed rheumatologists expect to significantly increase their use of Orencia SC, and this will drive up the overall Orencia brand share. Further, doctors project that in the next six months Orencia SC’s share will be almost equivalent to Orencia IV share. Physicians see little difference between the IV and SC forms of Orencia relative to the most important attributes for a biologic agent, and over three-quarters of surveyed doctors prefer Orencia (co-stimulation) as their first line non-TNF biologic therapy. “Orencia SC has done well in its first year of launch and seems to be growing the overall Orencia brand,” said BioTrends Immunology Therapeutic Class Director Paul Zimmerman. “However, the recent approval of Pfizer’s Xeljanz and the expected approval of a subcutaneous form of Roche/Genentech’s Actemra will offer rheumatologists even more therapy choices in an already crowded therapy market for RA.” LaunchTrends: Orencia SC is a series of four post-launch syndicated reports designed to track the uptake of Bristol-Myers Squibb’s Orencia SC at one month, three months, six months, and one year following launch. LaunchTrends assesses trial and use of new products, barriers to use, reasons to use, typical patient types, line of therapy, product perceptions, promotional efforts/messages and product satisfaction. In this Wave 4 report, BioTrends surveyed 102 rheumatologists and conducted in-depth qualitative interviews with a subset of the respondents. About BioTrends Research Group BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com. BioTrends is a Decision Resources Group company. About Decision Resources Group Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group atwww.DecisionResourcesGroup.com. All company, brand, or product names contained in this document may be trademarks of their respective holders. Contact: BioTrends Research Group, LLC Paul Zimmerman, 610-321-9427 firstname.lastname@example.org or Decision Resources Group Christopher Comfort, 781-993-2597 email@example.com
Although Orencia SC Enjoys a High Trial and Usage Rate One Year Post-Launch in Rheumatoid Arthritis, It Remains a Second-Line
Press spacebar to pause and continue. Press esc to stop.